NEXGEL expands partnership with STADA; gets $1M non-dilutive capital for N.A. launches

NEXGEL, INC.

Expansion includes digestive enzyme formulas and scar/stretch mark solutions for North America.
STADA will advance $1 million in non-dilutive capital to support product launches and marketing.
Partnership builds on existing relationship; targets consumer health market in North America.
CEO Adam Levy cites shared opportunity and acceleration of go-to-market strategy.

item 7.01item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.